Select your language
Select your language
Zur Bearbeitung des Projekts „AirBarn“ suchen wir ab November 2024 eine Wissenschaftliche Hilfskraft (m/w/d) mit ausdrücklichem Wunsch zur Anfertigung einer Masterarbeit zum Thema „Auftreten von Bioaerosolen und die Übertragung antimikrobieller Resistenzen in der Schweinehaltung“
Doctoral students from the Bernhard Nocht Institute for Tropical Medicine (BNITM), the Research Center Borstel, Leibniz Lung Center (FZB) and the Leibniz Institute of Virology (LIV) met for a three-day meeting on "Molecular Infectious Diseases Epidemiology". The three institutes organized the summer school as part of the Leibniz Center Infection (LCI) Graduate School as a joint event with the Hamburg Leibniz ScienceCampus "Integrative Analysis of Pathogen-induced Compartments" (InterACt). The summer school offered the doctoral students plenty of time for dialogue and networking.
Antimicrobial resistance (AMR) prevails as one of the leading causes of morbidity and mortality worldwide. In light of this pressing global concern, researchers of the Leibniz Research Alliance INFECTIONS have now added another puzzle piece to the bigger picture of AMR. Their study, published in Frontiers in Microbiology, sheds light on the intricate interplay of factors contributing to the proliferation of AMR in animal farming.
Join us for this innovative summer school on Antimicrobial Resistance: Navigating Between Access & Excess. Dive into interdisciplinary discussions, cutting-edge research, and innovative strategies to combat one of the greatest health challenges of our time. From economic implications to environmental impacts, from policy perspectives to scientific breakthroughs – this immersive program offers a unique opportunity for PhD students and postdocs across diverse research fields to shape the future of global health. Don't miss your chance to be part of this transformative journey!
Clostridioides difficile is a bacterium that occurs worldwide in the intestines of humans and animals. If the composition of the intestinal flora is out of balance, e.g. due to the intake of medication, these pathogens can become rampant. The toxins excreted by the bacteria then lead to sometimes severe intestinal inflammation, which can be fatal.
The inflammation is usually treated by administering an antibiotic that is effective against C. difficile. Three different antibiotics are currently recommended for this treatment: vancomycin, fidaxomicin or metronidazole (the latter in exceptional cases). In the last 25 years, however, the frequency of mutations has increased, which leads to a decreased susceptibility to these drugs and thus reduces the success of the therapy.